



May 2, 2024

Dear Vermont Attorney General's Office,

As required by 18 V.S.A. § 4637(b), Neurocrine Biosciences, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on April 30, 2024. The new products being launched are:

Product Name: INGREZZA® SPRINKLE (valbenazine) 40 mg capsules NDC: 70370-4040-01

Product Name: INGREZZA® SPRINKLE (valbenazine) 60 mg capsules NDC: 70370-4060-01

Product Name: INGREZZA® SPRINKLE (valbenazine) 80 mg capsules NDC: 70370-4080-01

Sincerely,

*Ingrid M. Brewer*

Ingrid M. Brewer

Sr. Manager, Contracts, Pricing & Trade

Neurocrine Biosciences, Inc.